Author Archives : Editorial Team

Home  >>  Author : Editorial Team

New member: Welcome in our cluster to HITS – Heidelberg Institute for Theoretical Studies

On July 11, 2018, Posted by , In News, By , With Comments Off on New member: Welcome in our cluster to HITS – Heidelberg Institute for Theoretical Studies

We are happy to welcome in our cluster the Heidelberg Institute for Theoretical Studies: The Heidelberg Institute for Theoretical Studies (HITS) was established in 2010 by the physicist and SAP co-founder Klaus Tschira (1940-2015) and the Klaus Tschira Foundation as a private, non-profit research institute. HITS conducts basic research in…

Boehringer Ingelheim Championing Early-Stage Life Science Entrepreneur Innovation in Heidelberg

On July 10, 2018, Posted by , In Press Releases, By ,, , With Comments Off on Boehringer Ingelheim Championing Early-Stage Life Science Entrepreneur Innovation in Heidelberg

Heidelberg 10.07.2018 BioRN as cross-cutting representative of the life science community supported Boehringer Ingelheim in the organisation, promotion and execution of this successful event. Open panel discussion during the Summer Networking Reception. Partnerships with early-stage companies often spark some of the most innovative research and development collaborations in the healthcare…

New member: Welcome in our cluster to Drees & Sommer

On July 10, 2018, Posted by , In News, By , With Comments Off on New member: Welcome in our cluster to Drees & Sommer

We are happy to welcome in our cluster Drees & Sommer. Drees & Sommer is an innovative partner for consulting, planning, construction and operation. For more than 45 years, the company has been supporting public- and private-sector owners and investors in all aspects of real estate. Managed by partners and…

New member: Welcome in our cluster to ERA Consulting

On July 5, 2018, Posted by , In News, By , With Comments Off on New member: Welcome in our cluster to ERA Consulting

We are happy to welcome in our cluster ERA Consulting. The ERA Consulting Group is one of the longest established and most experienced regulatory affairs and product development consulting groups serving the biopharmaceutical industry. “Our expertise covers quality, nonclinical and clinical aspects, both from the regulatory and development strategy perspective….

EMBL: Combining antibiotics changes their effectiveness

On July 5, 2018, Posted by , In News, By , With Comments Off on EMBL: Combining antibiotics changes their effectiveness

The effectiveness of antibiotics can be altered by combining them with each other, non-antibiotic drugs or even with food additives, EMBL researchers show. Depending on the bacterial species, some combinations stop antibiotics from working to their full potential whilst others begin to defeat antibiotic resistance, report EMBL researchers and collaborators…

Viscofan BioEngineering: Phase-I-trial approved for novel stem cell therapy for patients with ischemic cardiomyopathy

On July 4, 2018, Posted by , In News, By ,, , With Comments Off on Viscofan BioEngineering: Phase-I-trial approved for novel stem cell therapy for patients with ischemic cardiomyopathy

Viscofan BioEngineering, the biomedical business unit of the world market leader for collagenous sausage casings Viscofan announced today that the Spanish Agency for Medicines (AEMPS) has given green light to carry out a clinical phase-I-trial with Viscofan BioEngineering’s first product for regenerative medicine. The novel therapy consisting of stem cells…

BioRN Lounge: Dr. Juergen Gamer talked about Apogenix attractive immuno-oncology pipeline.

On June 27, 2018, Posted by , In Press Releases, By , , With Comments Off on BioRN Lounge: Dr. Juergen Gamer talked about Apogenix attractive immuno-oncology pipeline.

Heidelberg, 27.06.2018 BioRN Lounge: Dr. Juergen Gamer talked about “TNF Superfamily Receptor Modulators – Innovative Immuno-oncology Therapeutics” Once again, the BioRN Lounge was the occasion for the life science companies as well for scientists from our research institutes, to meet and chat about latest news and achievements. The BioRN Lounge…

DKFZ/Heidelberg University: New therapy makes blood cancer cells visible for the immune system

On June 27, 2018, Posted by , In News, By , , With Comments Off on DKFZ/Heidelberg University: New therapy makes blood cancer cells visible for the immune system

Chronic lymphocytic leukemia (CLL) is the most common type of blood cancer in adults. It can be treated with chemotherapy and oral drugs but this treatment cannot cure the cancer completely. Although the human immune system is capable of fighting the cancer cells, it often fails to notice them early…

DKFZ: 14 new breast cancer risk genes discovered

On June 26, 2018, Posted by , In News, By ,, , With Comments Off on DKFZ: 14 new breast cancer risk genes discovered

Many genetic markers associated with the familial breast cancer risk are outside the protein-coding regions of the genome and are likely to regulate the activity of neighboring genes. In a large international network, in which numerous DKFZ researchers were also involved, scientists have now combined genome-wide association studies with an…

EMBL: Miniature testing of drug pairs on tumour biopsies

On June 25, 2018, Posted by , In News, By ,, , With Comments Off on EMBL: Miniature testing of drug pairs on tumour biopsies

Microfluidic device in the Merten lab. IMAGE – Ramesh Utharala, EMBL Combinations of cancer drugs can be quickly and cheaply tested on tumour cells using a novel device developed by EMBL scientists. The research, reported in Nature Communications on June 22, marks the latest advancement in the field of personalised…